NetraMark Holdings Inc.

Equities

AIAI

CA64119M1059

Software

Market Closed - Canadian Securities Exchange 19:23:40 31/05/2024 BST 5-day change 1st Jan Change
0.265 CAD +6.00% Intraday chart for NetraMark Holdings Inc. -1.85% -24.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations CI
NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board CI
NetraMark Holdings Inc. Signs Contract with Pharmaceutical Company to Deliver Clinical Trial Insights Regarding Efficacy and Placebo Response CI
NetraMark Presenting New Data Showing Ability of its Proprietary NetraAI Clinical Trial Solution in PD Insights MT
NetraMark Holdings Inc. Announces the Presentation of New Data Demonstrating the Ability of its Proprietary NetraAI Clinical Trial Solution CI
NetraMark Holdings Inc. Signs Fourth Contract with Large Biopharmaceutical Company to Enhance Clinical Trial CI
NetraMark Holdings Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Netramark Holdings Inc. Announces Presentations of New Data Demonstrating the Application of Its Netraai Clinical Solution to Data Sets of Less Than 400 Patients CI
NetraMark Holdings Inc. to Present New Data Supporting the Potential of Its Proprietary NetraAI Clinical Trial Solution to De-Risk Clinical Trials CI
NetraMark Holdings Inc. Announces Launch of the NetraAI Lab Offering CI
NetraMark Up 8.6% After Reporting Third Contract With Biopharmaceutical Firm MT
Netramark Holdings Inc. Signs Third Contract with Biopharmaceutical Company CI
NetraMark Holdings Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates CI
NetraMark Holdings Inc. Signs Two Contracts with Large Biopharmaceutical Company to Enhance Clinical Trial Insights CI
257,550 Common Share of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2023. CI
30,000 Options of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2023. CI
NetraMark Holdings Inc. Announces Management Changes CI
NetraMark Holdings Inc. Signs Master Service Agreement with Large Biopharmaceutical Company CI
NetraMark Holdings Inc. announced that it has received CAD 2 million in funding CI
NetraMark Holdings Inc. announced that it expects to receive CAD 1.5 million in funding CI
NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
NetraMark Holdings Inc. Appoints Dr. Maryanne Rizk to Its Strategic Advisory Board CI
National Bank on Canadian ETFs with AI Exposure MT
Chart NetraMark Holdings Inc.
More charts
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
More about the company
  1. Stock Market
  2. Equities
  3. AIAI Stock
  4. News NetraMark Holdings Inc.
  5. Nurosene Health Names Chief Innovation and Regulatory Officer